Floatz logo

Tak-228

T Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)Phase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
73/ 100

Competitive context

80 Active assets in the T Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Children's Oncology Group
Phase 3BB
PEGASPARGASE
Children's Oncology Group
Phase 3BB
Daunorubicin
SWOG Cancer Research Network
Phase 3BB
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
University of Washington
Phase 3BB
MERCAPTOPURINE ANHYDROUS
SWOG Cancer Research Network
Phase 3BB

View all 50 →

Same molecule, other indications

Tak-228 is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
Recurrent Lung Non-Small Cell CarcinomaDormant
BB
Indicative ·
65 / 100
View asset →
pancreatic neuroendocrine tumorDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →